Tapewire

Nasdaq · USD

CGEM

Cullinan Therapeutics, Inc.

Export transactions ↓
Tapewire entity
4766
SEC CIK
0001789972
Parsed reports
252

Last 12 months

Inside the activity.

0 purchase rows · 28 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202501
Dec 202507
Jan 202601
Feb 2026013
Mar 202601
Apr 202600
May 202602
Jun 202600
Jul 202601
Aug 202601
Sep 202601
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
December 19, 2025 Filed Dec 22, 2025 22:00 UTC
Michaelson JenniferChief Scientific Officer
SaleCommon Stock 1,345 $10.01 $13,463.45
Disclosure

SEC source: 0001193125-25-328909 · ownership.xml · nonDerivative · entry 1

Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 132,635

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.99 to $10.09. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
December 18, 2025 Filed Dec 19, 2025 22:00 UTC
SUMER JACQUELYN LChief Legal Officer
SaleCommon Stock 3,480 $9.67 $33,651.60
Disclosure

SEC source: 0001193125-25-327033 · ownership.xml · nonDerivative · entry 1

SUMER JACQUELYN L · CIK 0001844824 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,432

F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.

F2 · balance_after: Includes 2,017 shares of common stock that the Reporting Person purchased pursuant to the Issuer's 2021 Employee Stock Purchase Plan for the purchase period of January 1, 2025 through June 30, 2025 that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Read SEC document
December 18, 2025 Filed Dec 19, 2025 22:00 UTC
Jones Jeffrey AlanChief Medical Officer
SaleCommon Stock 4,632 $9.67 $44,791.44
Disclosure

SEC source: 0001193125-25-327030 · ownership.xml · nonDerivative · entry 1

Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,532

F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.

Read SEC document
December 18, 2025 Filed Dec 19, 2025 22:00 UTC
Michaelson JenniferChief Scientific Officer
SaleCommon Stock 2,898 $9.67 $28,023.66
Disclosure

SEC source: 0001193125-25-327027 · ownership.xml · nonDerivative · entry 1

Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,980

F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.

Read SEC document
December 15, 2025 Filed Dec 16, 2025 22:00 UTC
Michaelson JenniferChief Scientific Officer
SaleCommon Stock 995 $11.90 $11,840.50
Disclosure

SEC source: 0001193125-25-321122 · ownership.xml · nonDerivative · entry 2

Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 136,878

F3 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025.

Read SEC document
December 12, 2025 Filed Dec 16, 2025 22:00 UTC
Michaelson JenniferChief Scientific Officer
SaleCommon Stock 2,148 $12.38 $26,592.24
Disclosure

SEC source: 0001193125-25-321122 · ownership.xml · nonDerivative · entry 1

Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 137,873

F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.

F2 · balance_after: Includes 2,017 shares of common stock that the Reporting Person purchased pursuant to the Issuer's 2021 Employee Stock Purchase Plan for the purchase period of January 1, 2025 through June 30, 2025 that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Read SEC document
November 24, 2025 Filed Nov 25, 2025 22:00 UTC
Michaelson JenniferChief Scientific Officer
SaleCommon Stock 4,000 $12.30 $49,200.00
Disclosure

SEC source: 0001193125-25-297549 · ownership.xml · nonDerivative · entry 1

Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 138,004

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025.

Read SEC document
October 28, 2025 Filed Oct 30, 2025 21:13 UTC PurchaseCommon stock, $0.0001 par value per share 165,667 $8.40 $1,391,685.63
Disclosure

SEC source: 0000902664-25-004662 · ownership.xml · nonDerivative · entry 1

Lynx1 Capital Management LP · CIK 0001910456 · 10% owner

Nichols Weston · CIK 0001746376 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 8,963,500

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.035 to $8.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

Read SEC document
October 17, 2025 Filed Oct 21, 2025 23:00 UTC PurchaseCommon Stock 32,217 $7.84 $252,565.17
Disclosure

SEC source: 0000902664-25-004499 · ownership.xml · nonDerivative · entry 4

Lynx1 Capital Management LP · CIK 0001910456 · 10% owner

Nichols Weston · CIK 0001746376 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 8,797,833

F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.78 to $7.85 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

Read SEC document
October 16, 2025 Filed Oct 21, 2025 23:00 UTC PurchaseCommon Stock 150,000 $8.86 $1,328,250.00
Disclosure

SEC source: 0000902664-25-004499 · ownership.xml · nonDerivative · entry 3

Lynx1 Capital Management LP · CIK 0001910456 · 10% owner

Nichols Weston · CIK 0001746376 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 8,765,616

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.68 to $9.22 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

Read SEC document
October 15, 2025 Filed Oct 21, 2025 23:00 UTC PurchaseCommon Stock 51,500 $7.94 $409,049.05
Disclosure

SEC source: 0000902664-25-004499 · ownership.xml · nonDerivative · entry 2

Lynx1 Capital Management LP · CIK 0001910456 · 10% owner

Nichols Weston · CIK 0001746376 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 8,615,616

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.88 to $8.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

Read SEC document
October 14, 2025 Filed Oct 21, 2025 23:00 UTC PurchaseCommon stock, $0.0001 par value per share ("Common Stock") 15,032 $7.59 $114,047.78
Disclosure

SEC source: 0000902664-25-004499 · ownership.xml · nonDerivative · entry 1

Lynx1 Capital Management LP · CIK 0001910456 · 10% owner

Nichols Weston · CIK 0001746376 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 8,564,116

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.50 to $7.68 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

Read SEC document
October 10, 2025 Filed Oct 10, 2025 22:58 UTC PurchaseCommon Stock 277,298 $7.36 $2,041,384.69
Disclosure

SEC source: 0000902664-25-004379 · ownership.xml · nonDerivative · entry 3

Lynx1 Capital Management LP · CIK 0001910456 · 10% owner

Nichols Weston · CIK 0001746376 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 8,549,084

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.87 to $7.46 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

Read SEC document
October 09, 2025 Filed Oct 10, 2025 22:58 UTC PurchaseCommon Stock 626,043 $6.70 $4,191,858.72
Disclosure

SEC source: 0000902664-25-004379 · ownership.xml · nonDerivative · entry 2

Lynx1 Capital Management LP · CIK 0001910456 · 10% owner

Nichols Weston · CIK 0001746376 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 8,271,786

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.60 to $6.90 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

Read SEC document
October 08, 2025 Filed Oct 10, 2025 22:58 UTC PurchaseCommon stock, $0.0001 par value per share ("Common Stock") 556,300 $6.46 $3,593,698.00
Disclosure

SEC source: 0000902664-25-004379 · ownership.xml · nonDerivative · entry 1

Lynx1 Capital Management LP · CIK 0001910456 · 10% owner

Nichols Weston · CIK 0001746376 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 7,645,743

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.40 to $6.60 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

Read SEC document
August 07, 2025 Filed Aug 8, 2025 21:30 UTC GrantStock Option (Right to Buy) · Derivative 79,456 $0.00 Strike: $7.03 $0.00
Disclosure

SEC source: 0000950170-25-106029 · ownership.xml · derivative · entry 1

Allen Andrew R · CIK 0001374539 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,456

Underlying: Common Stock · 79,456 shares

Expires 2035-08-07

F1 · derivative.exercise_date: The option represents a right to purchase a total of 79,456 shares of the Issuer's common stock, which shall vest as to one-third of the shares underlying the option on each of the first, second and third anniversaries of the grant date of the award, subject to the Reporting Person's continued service as a director on each such vesting date.

Read SEC document
August 07, 2025 Filed Aug 8, 2025 21:30 UTC
Doyle MittieDirector
GrantStock Option (Right to Buy) · Derivative 79,456 $0.00 Strike: $7.03 $0.00
Disclosure

SEC source: 0000950170-25-106028 · ownership.xml · derivative · entry 1

Doyle Mittie · CIK 0001918845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,456

Underlying: Common Stock · 79,456 shares

Expires 2035-08-07

F1 · derivative.exercise_date: The option represents a right to purchase a total of 79,456 shares of the Issuer's common stock, which shall vest as to one-third of the shares underlying the option on each of the first, second and third anniversaries of the grant date of the award, subject to the Reporting Person's continued service as a director on each such vesting date.

Read SEC document
June 12, 2025 Filed Jun 16, 2025 20:12 UTC GrantStock Option (Right to Buy) · Derivative 38,513 $0.00 Strike: $8.95 $0.00
Disclosure

SEC source: 0000950170-25-086732 · ownership.xml · derivative · entry 1

Rosenberg Anthony · CIK 0001466175 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,513

Underlying: Common Stock · 38,513 shares

Expires 2035-06-12

F1 · derivative.exercise_date: The option represents a right to purchase a total of 38,513 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 12, 2026 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date

Read SEC document
June 12, 2025 Filed Jun 16, 2025 20:10 UTC GrantStock Option (Right to Buy) · Derivative 38,513 $0.00 Strike: $8.95 $0.00
Disclosure

SEC source: 0000950170-25-086726 · ownership.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,513

Underlying: Common Stock · 38,513 shares

Expires 2035-06-12

F1 · derivative.exercise_date: The option represents a right to purchase a total of 38,513 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 12, 2026 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date

Read SEC document
June 12, 2025 Filed Jun 16, 2025 20:09 UTC GrantStock Option (Right to Buy) · Derivative 38,513 $0.00 Strike: $8.95 $0.00
Disclosure

SEC source: 0000950170-25-086721 · ownership.xml · derivative · entry 1

Meek David D. · CIK 0001555337 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,513

Underlying: Common Stock · 38,513 shares

Expires 2035-06-12

F1 · derivative.exercise_date: The option represents a right to purchase a total of 38,513 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 12, 2026 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date

Read SEC document
June 12, 2025 Filed Jun 16, 2025 20:14 UTC GrantStock Option (Right to Buy) · Derivative 38,513 $0.00 Strike: $8.95 $0.00
Disclosure

SEC source: 0000950170-25-086737 · ownership.xml · derivative · entry 1

Ryan David P. · CIK 0001951490 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,513

Underlying: Common Stock · 38,513 shares

Expires 2035-06-12

F1 · derivative.exercise_date: The option represents a right to purchase a total of 38,513 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 12, 2026 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date

Read SEC document
June 12, 2025 Filed Jun 16, 2025 20:07 UTC GrantStock Option (Right to Buy) · Derivative 38,513 $0.00 Strike: $8.95 $0.00
Disclosure

SEC source: 0000950170-25-086718 · ownership.xml · derivative · entry 1

Martin Anne-Marie · CIK 0001914495 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,513

Underlying: Common Stock · 38,513 shares

Expires 2035-06-12

F1 · derivative.exercise_date: The option represents a right to purchase a total of 38,513 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 12, 2026 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:00 UTC
AHMED NADIMDirector · President and CEO
SaleCommon Stock 12,529 $8.53 $106,872.37
Disclosure

SEC source: 0000950170-25-029199 · ownership.xml · nonDerivative · entry 1

AHMED NADIM · CIK 0001731193 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 430,621

F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:00 UTC
Jones Jeffrey AlanChief Medical Officer
SaleCommon Stock 4,895 $8.53 $41,754.35
Disclosure

SEC source: 0000950170-25-029201 · ownership.xml · nonDerivative · entry 1

Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,164

F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:00 UTC
Michaelson JenniferChief Scientific Officer
SaleCommon Stock 3,756 $8.53 $32,038.68
Disclosure

SEC source: 0000950170-25-029200 · ownership.xml · nonDerivative · entry 1

Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,004

F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:00 UTC
SUMER JACQUELYN LChief Legal Officer
SaleCommon Stock 3,756 $8.53 $32,038.68
Disclosure

SEC source: 0000950170-25-029197 · ownership.xml · nonDerivative · entry 1

SUMER JACQUELYN L · CIK 0001844824 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,895

F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.

Read SEC document
February 19, 2025 Filed Feb 21, 2025 23:00 UTC
Fenton Mary KayChief Financial Officer
GrantStock Option (Right to Buy) · Derivative 120,000 $0.00 Strike: $9.43 $0.00
Disclosure

SEC source: 0000950170-25-025027 · ownership.xml · derivative · entry 2

Fenton Mary Kay · CIK 0001378589 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2035-02-19

F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

Read SEC document
February 19, 2025 Filed Feb 21, 2025 23:00 UTC
Fenton Mary KayChief Financial Officer
GrantCommon Stock 60,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-025027 · ownership.xml · nonDerivative · entry 1

Fenton Mary Kay · CIK 0001378589 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

F1 · shares: The shares underlying the restricted stock unit vest on an annual basis over four years.

Read SEC document
February 19, 2025 Filed Feb 21, 2025 23:00 UTC
AHMED NADIMDirector · President and CEO
GrantStock Option (Right to Buy) · Derivative 360,000 $0.00 Strike: $9.43 $0.00
Disclosure

SEC source: 0000950170-25-025029 · ownership.xml · derivative · entry 2

AHMED NADIM · CIK 0001731193 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 360,000

Underlying: Common Stock · 360,000 shares

Expires 2035-02-19

F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

Read SEC document
February 19, 2025 Filed Feb 21, 2025 23:00 UTC
AHMED NADIMDirector · President and CEO
GrantCommon Stock 180,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-025029 · ownership.xml · nonDerivative · entry 1

AHMED NADIM · CIK 0001731193 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 443,150

F1 · shares: The shares underlying the restricted stock unit vest on an annual basis over four years.

Read SEC document
February 19, 2025 Filed Feb 21, 2025 23:00 UTC
SUMER JACQUELYN LChief Legal Officer
GrantStock Option (Right to Buy) · Derivative 100,000 $0.00 Strike: $9.43 $0.00
Disclosure

SEC source: 0000950170-25-025030 · ownership.xml · derivative · entry 2

SUMER JACQUELYN L · CIK 0001844824 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2035-02-19

F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

Read SEC document
February 19, 2025 Filed Feb 21, 2025 23:00 UTC
SUMER JACQUELYN LChief Legal Officer
GrantCommon Stock 50,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-025030 · ownership.xml · nonDerivative · entry 1

SUMER JACQUELYN L · CIK 0001844824 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,651

F1 · shares: The shares underlying the restricted stock unit vest on an annual basis over four years.

Read SEC document
February 19, 2025 Filed Feb 21, 2025 23:00 UTC
Michaelson JenniferChief Scientific Officer
GrantStock Option (Right to Buy) · Derivative 100,000 $0.00 Strike: $9.43 $0.00
Disclosure

SEC source: 0000950170-25-025032 · ownership.xml · derivative · entry 2

Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2035-02-19

F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

Read SEC document
February 19, 2025 Filed Feb 21, 2025 23:00 UTC
Michaelson JenniferChief Scientific Officer
GrantCommon Stock 50,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-025032 · ownership.xml · nonDerivative · entry 1

Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,760

F1 · shares: The shares underlying the restricted stock unit vest on an annual basis over four years.

Read SEC document
February 19, 2025 Filed Feb 21, 2025 23:00 UTC
Savill CorrineChief Business Officer
GrantStock Option (Right to Buy) · Derivative 75,000 $0.00 Strike: $9.43 $0.00
Disclosure

SEC source: 0000950170-25-025031 · ownership.xml · derivative · entry 2

Savill Corrine · CIK 0001837524 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2035-02-19

F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

Read SEC document
February 19, 2025 Filed Feb 21, 2025 23:00 UTC
Savill CorrineChief Business Officer
GrantCommon Stock 37,500 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-025031 · ownership.xml · nonDerivative · entry 1

Savill Corrine · CIK 0001837524 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 240,990

F1 · shares: The shares underlying the restricted stock unit vest on an annual basis over four years.

Read SEC document
February 19, 2025 Filed Feb 21, 2025 23:00 UTC
Jones Jeffrey AlanChief Medical Officer
GrantStock Option (Right to Buy) · Derivative 130,000 $0.00 Strike: $9.43 $0.00
Disclosure

SEC source: 0000950170-25-025028 · ownership.xml · derivative · entry 2

Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 130,000 shares

Expires 2035-02-19

F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

Read SEC document
February 19, 2025 Filed Feb 21, 2025 23:00 UTC
Jones Jeffrey AlanChief Medical Officer
GrantCommon Stock 65,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-025028 · ownership.xml · nonDerivative · entry 1

Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 179,059

F1 · shares: The shares underlying the restricted stock unit vest on an annual basis over four years.

Read SEC document
January 06, 2025 Filed Jan 7, 2025 22:00 UTC
Michaelson JenniferChief Scientific Officer
SaleCommon Stock 4,000 $12.51 $50,040.00
Disclosure

SEC source: 0000950170-25-002946 · ownership.xml · nonDerivative · entry 1

Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 95,760

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on January 5, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.32 to $12.62. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.

Read SEC document
December 24, 2024 Filed Dec 27, 2024 23:00 UTC
AHMED NADIMDirector · President and CEO
SaleCommon Stock 8,400 $11.87 $99,708.00
Disclosure

SEC source: 0000950170-24-140856 · ownership.xml · nonDerivative · entry 1

AHMED NADIM · CIK 0001731193 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 263,150

F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.

Read SEC document
December 18, 2024 Filed Dec 20, 2024 22:00 UTC
Michaelson JenniferChief Scientific Officer
SaleCommon Stock 4,693 $11.41 $53,547.13
Disclosure

SEC source: 0000950170-24-139125 · ownership.xml · nonDerivative · entry 1

Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,760

F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.

Read SEC document
December 18, 2024 Filed Dec 20, 2024 22:00 UTC
Jones Jeffrey AlanChief Medical Officer
SaleCommon Stock 4,632 $11.41 $52,851.12
Disclosure

SEC source: 0000950170-24-139124 · ownership.xml · nonDerivative · entry 1

Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,059

F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.

Read SEC document
December 18, 2024 Filed Dec 20, 2024 22:00 UTC
SUMER JACQUELYN LChief Legal Officer
SaleCommon Stock 3,482 $11.41 $39,729.62
Disclosure

SEC source: 0000950170-24-139123 · ownership.xml · nonDerivative · entry 1

SUMER JACQUELYN L · CIK 0001844824 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,651

F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.

Read SEC document
December 12, 2024 Filed Dec 16, 2024 22:00 UTC
Michaelson JenniferChief Scientific Officer
SaleCommon Stock 3,489 $12.52 $43,682.28
Disclosure

SEC source: 0000950170-24-136726 · ownership.xml · nonDerivative · entry 1

Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,453

F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.

Read SEC document
November 05, 2024 Filed Nov 7, 2024 22:30 UTC
Michaelson JenniferChief Scientific Officer
SaleCommon Stock 8,000 $15.64 $125,120.00
Disclosure

SEC source: 0000950170-24-123538 · ownership.xml · nonDerivative · entry 1

Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 107,942

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on January 5, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.25 to $15.98. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
September 05, 2024 Filed Sep 9, 2024 21:30 UTC
Michaelson JenniferChief Scientific Officer
SaleCommon Stock 8,000 $18.09 $144,720.00
Disclosure

SEC source: 0000950170-24-104820 · ownership.xml · nonDerivative · entry 1

Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 115,942

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on January 5, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.79 to $18.55. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 08, 2024 Filed Aug 9, 2024 21:00 UTC
Thistle MaryDirector
GrantStock Option (Right to Buy) · Derivative 25,743 $0.00 Strike: $16.38 $0.00
Disclosure

SEC source: 0000950170-24-094861 · ownership.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,743

Underlying: Common Stock · 25,743 shares

Expires 2034-08-08

F1 · derivative.exercise_date: The option represents a right to purchase a total of 25,743 shares of the Issuer's common stock, which shall vest as to one-third of the shares underlying the option on each of the first, second and third anniversaries of the grant date of the award, subject to the Reporting Person's continued service as a director on each such vesting date.

Read SEC document
July 05, 2024 Filed Jul 9, 2024 21:30 UTC
Michaelson JenniferChief Scientific Officer
SaleCommon Stock 8,000 $16.33 $130,640.00
Disclosure

SEC source: 0000950170-24-082485 · ownership.xml · nonDerivative · entry 1

Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 123,942

F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on January 5, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.97 to $16.77. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 01, 2024 Filed Jul 2, 2024 23:30 UTC
Michaelson JenniferChief Scientific Officer
GrantCommon Stock 2,360 $9.00 $21,240.00
Disclosure

SEC source: 0000950170-24-080961 · ownership.xml · nonDerivative · entry 1

Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,942

F2 · price: In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on January 2, 2024.

F1 · acquired: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c).

Read SEC document
June 26, 2024 Filed Jun 27, 2024 23:00 UTC GrantStock Option (Right to Buy) · Derivative 15,806 $0.00 Strike: $16.50 $0.00
Disclosure

SEC source: 0000950170-24-078677 · ownership.xml · derivative · entry 1

Rosenberg Anthony · CIK 0001466175 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,806

Underlying: Common Stock · 15,806 shares

Expires 2034-06-26

F1 · derivative.exercise_date: The option represents a right to purchase a total of 15,806 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 26, 2025 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.